|
(PQ #10) Gut-brain interactions underlying chemotherapy-induced behavioral comorbidities
|
5R01CA216290-02
|
$309,819
|
PYTER, LEAH
|
OHIO STATE UNIVERSITY
|
|
(PQ#9): Altered mitochondrial transport and chemotherapy-induced peripheral neuropathy
|
5R21CA215985-02
|
$165,000
|
CHANG, KAREN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
3R01CA206025-03S1
|
$52,355
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
5R01CA206025-03
|
$630,724
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQ11) Dietary strategies to enhance FOLFOX cancer therapies
|
1R21CA231255-01
|
$189,744
|
ROSENBERG, DANIEL
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)
|
1R01CA231267-01
|
$460,814
|
FEHRENBACHER, JILL
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy
|
1R01CA219637-01A1
|
$281,441
|
DAMAJ, M IMAD
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer
|
5R01CA219880-02
|
$670,182
|
PALUCKA, ANNA KAROLINA
|
JACKSON LABORATORY
|
|
(PQ5) Exploring the Biological Distinctions between HIV-related and Endemic Pediatric Kaposi Sarcoma in a Kaposi Sarcoma-Associated Herpesvirus-Endemic Region of Africa
|
5R21CA217137-02
|
$196,947
|
EL-MALLAWANY, NADER
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
|
3R01CA205967-03S2
|
$230,366
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INST
|
|
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
|
5R01CA205967-03
|
$386,588
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INST
|
|
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity
|
5R01CA205101-03
|
$384,612
|
SKALA, MELISSA
|
MORGRIDGE INSTITUTE FOR RESEARCH, INC.
|
|
(PQ9) Characterization and prophylactic treatment of chemotherapy-induced long-term adverse sequelae
|
5R01CA208634-03
|
$560,277
|
JURECIC, ROLAND
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
(PQ9) The role of Bclw (bcl2l2) in preventing chemotherapy induced neuropathy
|
5R01CA205255-03
|
$577,463
|
SEGAL, ROSALIND
|
DANA-FARBER CANCER INST
|
|
(PQ9)A redox-mediated mechanism of chemotherapy-induced cognitive impairment
|
5R01CA217934-02
|
$463,899
|
ST CLAIR, DARET
|
UNIVERSITY OF KENTUCKY
|
|
(PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathy
|
5R01CA205166-02
|
$537,592
|
KELLEY, MARK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
1/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research
|
3U54CA156734-08S1
|
$64,152
|
COLON-CARMONA, ADAN
|
UNIVERSITY OF MASSACHUSETTS BOSTON
|
|
1/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research
|
5U54CA156734-08
|
$1,691,502
|
COLON-CARMONA, ADAN
|
UNIVERSITY OF MASSACHUSETTS BOSTON
|
|
1/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
|
1U54CA233396-01
|
$1,008,781
|
REAMS, ROMONIA
|
FLORIDA AGRICULTURAL AND MECHANICAL UNIV
|
|
2/2 Langston University-UNTHSC Partnership for Cancer Research and Education
|
1P20CA233355-01
|
$255,958
|
VISHWANATHA, JAMBOOR
|
UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
|
|
2/2 NCCU-LCCC Partnership in Cancer Research
|
5U54CA156733-09
|
$1,003,901
|
EARP, HENRY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
2/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research
|
5U54CA156732-08
|
$1,870,359
|
VISWANATH, KASISOMAYAJULA
|
DANA-FARBER CANCER INST
|
|
2/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
|
1U54CA233444-01
|
$1,054,795
|
ODEDINA, FOLAKEMI
|
UNIVERSITY OF FLORIDA
|
|
2/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
5U54CA118623-13
|
$1,101,004
|
TROY, ROBERTA
|
TUSKEGEE UNIVERSITY
|
|
2D and 3D Contrast-enhanced Ultrasound Evaluation of HCC Chemoembolization
|
5R01CA194307-03
|
$105,860
|
EISENBREY, JOHN
|
THOMAS JEFFERSON UNIVERSITY
|
|
3/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
|
1U54CA233465-01
|
$1,141,251
|
CARPTEN, JOHN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
3D biomimetic image-based stromal models of pancreatic cancer for drug screening
|
1R21CA224280-01A1
|
$213,829
|
CAMPAGNOLA, PAUL
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
3D Dynamic Contrast-Enhanced US for Monitoring Chemotherapy of Liver Metastasis
|
5R01CA195443-03
|
$208,861
|
KAMAYA, AYA
|
STANFORD UNIVERSITY
|
|
A combined single cell gene expression and enzyme activity assay to study chemotherapy resistance in pancreatic ductal adenocarcinoma
|
1F31CA228223-01
|
$35,681
|
PETERSEN, BRAE
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
A functional genomics approach to determine the mechanism of cellular response to new anti-cancer
|
5R00CA204602-03
|
$249,000
|
GILBERT, LUKE
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
A genomewide discovery of chemoresistance-associated noncoding RNAs in human cancers
|
1R21CA226303-01
|
$176,175
|
HE, TONG-CHUAN
|
UNIVERSITY OF CHICAGO
|
|
A multiplexed approach to improve tumoral targeting and chemotherapeutic treatment
|
1R01CA222802-01A1
|
$412,139
|
LAW, BENEDICT
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
A network platform to connect drug response and prognosis phenotypes for cancers
|
5R01CA196631-03
|
$395,911
|
LI, HU
|
MAYO CLINIC ROCHESTER
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
A novel microfluidic device to predict brain cancer prognosis and response to therapy
|
1R01CA216855-01A1
|
$496,519
|
QUINONES-HINOJOSA, ALFREDO
|
MAYO CLINIC JACKSONVILLE
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
5R01CA183984-04
|
$473,915
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
A novel more effective genotoxic therapy for ovarian cancer
|
1R37CA215436-01A1
|
$368,288
|
SIMPKINS, FIONA
|
UNIVERSITY OF PENNSYLVANIA
|
|
A Novel PET Probe for Use in Cancer Diagnostics
|
5R44CA216539-03
|
$999,412
|
MOORE, MELISSA
|
SOFIE BIOSCIENCES, INC.
|
|
A novel target to overcome chemoresistance in breast cancer
|
1R21CA223389-01
|
$203,580
|
RINCON, MERCEDES
|
UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
|
|
A novel, short isoform of the +TIP microtubule (MT) binding protein CLIP170 confers taxane resistance by obstructing the MT pore.
|
1R01CA228512-01
|
$504,230
|
GIANNAKAKOU, PARASKEVI
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
A p53/NFkB-mediated metabolic mechanism for chemotherapy protection
|
5R01CA183074-05
|
$335,113
|
YUAN, ZHI-MIN
|
HARVARD SCHOOL OF PUBLIC HEALTH
|
|
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
|
4R44CA217591-02
|
$1,125,311
|
KAHN, STUART
|
SYNTRIX BIOSYSTEMS, INC.
|
|
A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome
|
5R44CA213519-02
|
$1
|
ISAACMAN, STEVEN
|
NANOMETICS, LLC
|
|
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas
|
5R01CA198076-04
|
$546,873
|
PORTNOW, JANA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A Phase I trial combining IV fenretinide and IV safingol to target overproduction
|
5R44CA183316-03
|
$473,425
|
SIMPSON, WILLIAM
|
CERRX, INC.
|
|
A Prognostic Blood Test to Monitor Pancreatic Cancer Treatment by MiRNA Profiling
|
2R44CA199058-02
|
$999,597
|
SARAF, RAVI
|
VAJRA INSTRUMENTS, INC.
|
|
A Prospective Study of the Impact of Breast Cancer on Symptoms and Functioning
|
5R01CA199137-04
|
$55,401
|
AVIS, NANCY
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
A Quality Control Program for Quantitative MRI Data Acquisition and Analysis in Multi-site Clinical Trials
|
1R44CA235820-01
|
$224,422
|
KARAULANOV, TODOR
|
QALIBREMD, INC.
|
|
A randomized trial of lifestyle guidelines on breast cancer biomarkers and treatment adherence
|
3R01CA207753-02S2
|
$76,309
|
SANFT, TARA
|
YALE UNIVERSITY
|
|
A randomized trial of lifestyle guidelines on breast cancer biomarkers and treatment adherence
|
5R01CA207753-02
|
$663,278
|
SANFT, TARA
|
YALE UNIVERSITY
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|